See today's BioWorld
To read the full story, subscribe or sign in.

Artios, Novartis combining DDR approach with radioligands in three-year, $1.3B deal

April 7, 2021
By Nuala Moran
LONDON – DNA damage response (DDR) specialist Artios Pharma Ltd. has signed a potential $1.3 billion deal to apply its technology to discover drugs that will work in combination with Novartis AG’s radioligand therapies.
BioWorld Deals and M&A Cancer